Wu Jieping Medical Foundation
18
1
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
5.6%
1 terminated/withdrawn out of 18 trials
80.0%
-6.5% vs industry average
17%
3 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
Role: collaborator
Shared Decision Making in Patients With Lung Cancer
Role: collaborator
Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy
Role: collaborator
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery
Role: collaborator
Clinical Research on Shenfu Injection in Septic Patients
Role: collaborator
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Role: collaborator
Combined Segmentectomy Versus Lobectomy for Stage IA Lung Adenocarcinoma With Ground-glass Component of Prospective, Randomized, Controlled Clinical Study
Role: collaborator
Peripheral Oxygen Saturation (SpO2) Directed Oxygen Therapy
Role: collaborator
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
Role: collaborator
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
Role: collaborator
Study on the Level of Neuromuscular Blockade
Role: collaborator
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS
Role: collaborator
Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals
Role: collaborator
Comparison of Balanced Crystalloids and Normal Saline in Septic Patients
Role: collaborator
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
Role: lead
Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
Role: collaborator
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
Role: collaborator
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment
Role: lead
All 18 trials loaded